DESERVE showed significant benefits in NHS healthcare savings

SVMPharma’s real-world evidence helped deliver a real-world study looking at the clinical outcomes of triptorelin vs other LHRH agonists (LHRHa) in clinical practice for prostate cancer patients. Our real-world evidence helped show a significant reduction in healthcare resource utilisation for the NHS as well as maintenance in PSA control (a biomarker in prostate cancer) when switching to a 6-monthly formulation of triptorelin from the existing 3-monthly formulations of LHRHa in real-world clinical practice.




Switching to A 6-Monthly Triptorelin Formulation for Prostate Cancer (Pca) Reduces Patient–Nhs Interactions and Hospital Resource use: Real World Evidence (Rwe) from Project Deserve (Decapeptyl Service Evaluation)

P Cornford, K Jefferson, O Cole, JS Gilbody, V Nayar, G Auddy

Objective: In the UK, PCa is the second most common male cancer resulting in over 10,000 deaths annually. LHRH agonists (LHRHa), a type of androgen deprivation therapy, are used to help control PCa and delay progression. LHRHa injections are available as 1-, 3- and 6-monthly formulations. Triptorelin is the only LHRHa in the UK available as a 6-monthly formulation. DESERVE aimed to collect RWE about clinical and practical outcomes for patients starting on, or switching to, 6-monthly triptorelin.

Method: A customised data collection programme was designed including up to 2 years of data entered retrospectively by physicians from patient records at three UK hospitals and prospectively updated over a 5-month period. All patients on 6-monthly triptorelin were eligible for entry. The primary outcome measure was change in the number of patient–NHS interactions (patient reviews, PSA tests and LHRHa injections).

Results: 115 patient records were entered; records for 88 patients had complete data and were included in the analysis. 47 were newly diagnosed and initiated on 6-monthly triptorelin; 41 were switched from any 3-monthly LHRHa to 6-monthly triptorelin. For switch patients, there was a statistically significant reduction in the number of reviews (by 48.4%; p<0.0001), injections (48.4%; p<0.0001) and PSA tests (29.8%; p<0.0001) in the 12 months following switch versus 12 months before. The total number of patient–NHS interactions was significantly reduced (43.5%; p<0.0001). At 12 months, median PSA was 1.30 ng/mL (23.50 ng/mL at diagnosis) for newly treated patients and 0.24 ng/mL (0.35 ng/mL at switch) for switch patients. No safety issues were identified.

Conclusions: Patient–NHS interactions were significantly reduced and PSA control was maintained with 6-monthly triptorelin vs any 3-monthly LHRHa, which translates into NHS savings and improvement in the overall patient experience. Use of 6-monthly triptorelin may therefore offer advantages over 3-monthly formulations for patients, prescribers and payors

Click here to see the source material


About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

Posted in Blogs.